Join a Study2018-08-17T12:56:44+00:00

Medical trials are currently being conducted at Alivation—this is your chance to help science and medicine. Study-related exams, tests and medication will be provided at no cost, and you may be compensated for your time.

Review the open research studies below and apply for the one(s) you qualify for. Bookmark this page and check back often, as studies are often updated and we’re always recruiting qualified candidates. Check out our list of studies or contact us with any questions. Participation in all research is voluntary and not everyone may qualify. If you are interested in learning how you can assist in scientific research, or if you’d like to participate in a study for a condition not listed, please call 402.476.6060, option 4.

If you would like to submit research study ideas, or if you have any questions about studies, please send an email to research@alivation.com. 

CURRENT PHARMACEUTICAL RESEARCH TRIALS:
  • Phase 2/3 study evaluating AXS-05 (bupropion hydrochloride and dextromethorphan hydrobromide monohydrate) for individuals with treatment-resistant depression
  • Duration of the study is 3 months, consisting of 10 visits to the clinic
  • Must be currently experiencing moderate to severe symptoms of depression
  • History of inadequate response to an antidepressant
  • Compensation for your time and travel is offered
      • Phase 3 study evaluating Rapastinel as adjunctive therapy for patients diagnosed with Major Depressive Disorder
      • Duration of the study is 1 month, consisting of 12 visits to the clinic
      • Must be currently experiencing moderate to severe symptoms of depression
      • Must be currently on an antidepressant and having an inadequate response to the treatment
      • Compensation for your time and travel is offered
  • Phase 3 clinical study of Levomilnacipran ER in adolescents with Major Depressive Disorder.
  • Duration of the study is 13 weeks, consisting of 7 visits, with a 12-week follow-up.
  • Must be currently experiencing moderate to severe symptoms of depression.
  • Will have to wash off of existing antidepressant medication if currently on one.
  • Compensation for your time and travel is offered.
  • Phase 3 clinical study of SPD489 in preschool children aged 4-5 years with ADHD.
  • Duration of the study is 12 weeks, consisting of 9-10 visits.
  • Weigh at least 44 lbs, and BMI less than 99th.
  • Will have to wash off of existing psychiatric medication if currently on any.
  • Subject’s parent(s) or legally authorized representative (LAR) must be able to provide informed consent and comply with study requirements.
  • Compensation for your time and travel is offered.
  • Phase 3 clinical study of Adjunctive Molindone Hydrochloride ER for the treatment of Impulsive aggression in pediatric patients with ADHD.
  • Duration of the study is 13 weeks, consisting of 7 visits.
  • Currently on a monotherapy treatment for ADHD.
  • BMI less than 99th.
  • Subject’s parent(s) or legally authorized representative (LAR) must be able to provide informed consent and comply with study requirements.
  • Compensation for your time and travel is offered.
  • Phase 3 study evaluating SPN-812 ER (Viloxazine hydrochloride) for children and adolescents with ADHD or currently experiencing symptoms of ADHD
  • Duration of the study is 2 months, consisting of 8 visits to the clinic (with the option of enrolling into an open-label extension study afterward that lasts for 36 months)
  • Must be experiencing symptoms of ADHD
  • Not currently on any medications or is willing to come off of the medications for the duration of the study
  • Compensation for your time and travel is offered
      • Phase 2 study evaluating NBI-98854 (valbenazine tosylate) for the treatment of Tourette’s
      • Duration of the study is 11 months, consisting of 17 visits to the clinic
      • Must be experiencing motor and vocal tics that cause distress or interfere with work, school, or social function
      • Compensation for your time and travel is offered
CURRENT TMS RESEARCH TRIALS:
  • Prospective, randomized clinical study of deep transcranial magnetic stimulation (dTMS) for smoking cessation.
  • Duration of the study is 6 weeks, consisting of 20 visits.
  • Must be smoking ≥ 10 cigarettes/day and highly motivated to quit.
  • Cannot be on any psychotropic medications.
  • History of significant head traumas, epilepsy, seizure or frequent and severe headaches/migraines is excluded.
  • Compensation for your time and travel is offered.
Upcoming Studies

Our dedicated research staff is certified to conduct clinical trials according to Good Clinical Practices (GCP), adhering to all written standard operating procedures (SOPs) and HIPPA regulations.